Agreed its not a battle between ePAT and RAP. They both should do well in an expanding market sector. For ePAT, RAP is a good path finder to show what is possible if you get it right and its a guide to potential market cap's. Watching how RAP go about their FDA approval will also be helpful for ePAT. Hopefully, ePAT get the benefit of being a fast follower albeit with a different product but in the same market sector.
- Forums
- ASX - By Stock
- Ann: Change of Company Name-MNQ.AX
Agreed its not a battle between ePAT and RAP. They both should...
-
- There are more pages in this discussion • 33 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add MNQ (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
ACW
ACTINOGEN MEDICAL LIMITED
Will Souter, CFO
Will Souter
CFO
Previous Video
Next Video
SPONSORED BY The Market Online